Karyopharm Therapeutics Inc. (KPTI) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Karyopharm Therapeutics Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Karyopharm Therapeutics Inc.'s filing signal
turned negative.
earningsVibe SuperAnalyst™ Verdict:
TURNED NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-0.35%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Karyopharm Therapeutics Inc. actually do?
Answer:
Karyopharm Therapeutics is a commercial-stage pharmaceutical company focused on developing and commercializing novel cancer therapies targeting nuclear export. Its lead product, XPOVIO (selinexor), is an oral XPO1 inhibitor approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company is actively pursuing further indications for selinexor, with key clinical programs in myelofibrosis and endometrial cancer. Karyopharm also has a next-generation XPO1 inhibitor, eltanexor, in development. Commercialization in the U.S. is handled by its internal sales force, while international markets are managed through partnerships with companies like Menarini and Antengene.
Question:
What are Karyopharm Therapeutics Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by net product sales of XPOVIO in the U.S. and license and royalty revenue generated from international partnerships.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required